Post operative dynamism of NSCLC tumor markers (CEA, CYFRA 21.1, NSE, TK, TPS)
J. Safranek, O. Topolcan, J. Klecka, V. Spidlen, J. Vodicka, V. Simanek (Pilsen, Czech Republic)
Source: Annual Congress 2006 - Lung cancer and other malignancies
Session: Lung cancer and other malignancies
Session type: Thematic Poster Session
Number: 4129
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Safranek, O. Topolcan, J. Klecka, V. Spidlen, J. Vodicka, V. Simanek (Pilsen, Czech Republic). Post operative dynamism of NSCLC tumor markers (CEA, CYFRA 21.1, NSE, TK, TPS). Eur Respir J 2006; 28: Suppl. 50, 4129
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Importance of tumour markers CYFRA 21-1 and NSE serum concentration values in diagnosis and esteem of nonmicrocelullar lung cancer expansion Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
MonoTotal vs. other cytokeratin markers in NSCLC Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
The correlation between mediastinal lymphadenopathy positivity proved by mediastinoscopy and serum levels of vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in NSCLC cases Source: Annual Congress 2007 - Diagnosis of thoracic malignancies Year: 2007
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Carcinoembryonic antigen mRNA analysis detects micrometastatic cells in blood from lung cancer patients Source: Eur Respir J 2003; 22: 418-421 Year: 2003